Lipocine, Inc. (LPCN)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about Lipocine, Inc. (LPCN)
Company Performance

Current Price

as of Oct 16, 2024

$5.08

P/E Ratio

N/A

Market Cap

$27.17M

Description

Lipocine, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of the delivery of drugs using proprietary delivery technology. It offers TLANDO, an oral testosterone replacement therapy. The company was founded on October 13, 2011 and is headquartered in Salt Lake City, UT.

Metrics

Overview

  • HQSalt Lake City, UT
  • SectorHealth Technology
  • IndustryPharmaceuticals: Major
  • TickerLPCN
  • Price$5.080.00%

Trading Information

  • Market Cap$27.17M
  • Float97.09%
  • Average Daily Volume (1m)22,534
  • Average Daily Volume (3m)30,923
  • EPS-$1.60

Company

  • Revenue$7.76M
  • Rev Growth (1yr)N/A
  • Net Income-$3.07M
  • Gross Margin90.50%
  • EBITDA Margin-3,666.68%
  • EBITDA-$3.28M
  • EV$21.49M
  • EV/Revenue2.77
  • P/EN/A
  • P/S3.50
  • P/B1.28
Documents
SEC Filings
8-K (2024-10-16)
8-K (2024-10-10)
8-K (2024-10-08)
8-K (2024-10-02)
8-K (2024-09-30)
8-K (2024-09-05)
8-K (2024-08-27)
8-K (2024-08-08)
8-K (2024-06-25)
8-K (2024-06-10)
8-K (2024-06-05)
8-K (2024-06-03)
8-K (2024-05-09)
8-K (2024-05-08)
8-K (2024-05-01)
8-K (2024-04-29)
8-K (2024-04-26)
8-K (2024-04-11)
8-K (2024-03-28)
8-K (2024-03-25)
8-K (2024-03-07)
8-K (2024-03-06)
8-K (2024-02-12)
8-K (2024-01-18)
8-K (2024-01-09)
8-K (2023-12-19)
8-K (2023-11-13)
8-K (2023-11-08)
8-K (2023-11-01)
8-K (2023-10-26)
8-K (2023-10-24)
8-K (2023-10-06)
8-K (2023-09-19)
8-K (2023-08-10)
8-K (2023-07-27)
8-K (2023-06-26)
8-K (2023-06-23)
8-K (2023-06-14)
8-K (2023-06-07)
8-K (2023-05-31)
8-K (2023-05-16)
8-K (2023-05-11)
8-K (2023-05-05)
8-K (2023-04-03)
8-K (2023-03-13)
8-K (2023-03-10)
8-K (2023-01-11)
8-K (2023-01-05)
10-Q (2024-08-08)
10-Q (2024-05-09)
10-Q (2023-11-08)
10-Q (2023-08-10)
10-Q (2023-05-11)
10-K (2024-03-07)
10-K (2023-03-10)
Factset Street Account
Lipocine reports Q3 EPS ($1.27) vs year-ago ($0.52) ($2.52, 0.00) (2023-11-08T13:06:57Z)
Lipocine releases late breaking presentation on LPCN 1148 Phase 2 results at The Liver Meeting 2023 ($2.55, +0.05) (2023-11-13T19:50:35Z)
Lipocine provides update on LPCN 1154 study after FDA meeting ($2.41, 0.00) (2023-10-26T12:12:59Z)
Lipocine provides upcoming milestones - slides - 8-K ($2.50, 0.00) (2023-10-24T10:12:49Z)